Coronavirus antibodies dwindled to undetectable levels after just two or three months for 40% of asymptomatic people and 13% of symptomatic people, according to a new study.
Overall, asymptomatic people showed “a weaker immune response” in the months after they were exposed to the coronavirus.
A poor immune response in people who recover from the virus may not bode well for the development of an effective vaccine.
People who develop coronavirus-fighting antibodies might not keep them very long, especially if they didn’t have symptoms.
After just a few months, recovered coronavirus patients may rapidly lose antibodies — blood proteins that fight off the virus and can prevent reinfection — according to a study published Thursday in the journal Nature Medicine. The finding raises new questions about the idea of immunity passports and could be cause for concern about the development of an effective vaccine.
The researchers tested for antibodies in 37 people who had fallen ill and recovered from the virus in the Wanzhou district of China. They also tested 37 others who had tested positive for the virus but never showed symptoms.
The study was meant to address two key questions that will inform how the world responds to the pandemic in the coming months: Do most people develop immunity after infection? And how long does that protection last?
STR/AFP via Getty Images
For many of the participants in the study, however, antibodies only seemed to last a couple months. About eight weeks after recovery, antibodies dropped to undetectable levels in 40% of the asymptomatic people and in 13% of those who had symptoms.
The asymptomatic people overall had “a weaker immune response,” the study authors wrote. Their research is some of the first into the immune response among asymptomatic people; previous studies have found that most people who show COVID-19 symptoms develop antibodies.
It’s unclear if low levels of antibodies, even undetectable levels, are enough to confer immunity. Some research has suggested that even low antibody counts could still be enough to prevent reinfection.
The Wanzhou study’s sample size was small, though, and antibody tests can be unreliable on a person-to-person basis.
Different types of immunity
Omar Marques/Getty Images
The Wanzhou researchers tested for two types of antibodies: immunoglobulin G (IgG) and immunoglobulin M (IgM).
In general, our bodies make IgM first in response to a viral infection, whereas IgG develops over a longer period of time. That means IgG is usually a better indicator of long-term immunity.
“Even though we don’t know what’s going on with this disease yet, if IgG confers immunity, that’s the more important one that has implications for going back to work,” Ania Wajnberg, the director of clinical antibody testing at Mount Sinai Hospital in New York, previously told Business Insider.
Seven people from the new study’s asymptomatic group and six from the symptomatic group did not test positive for IgG antibodies three to four weeks after they were exposed to the virus. Even more participants did not have detectable levels of IgM.
After just eight weeks, IgG levels had declined in all but three of the people who started out with detectable levels. The drop was steep: a median decrease of 71% for the asymptomatic group and 76% for the symptomatic group. Some participants no longer had detectable IgG at all. The symptomatic people started out with “significantly higher” levels, according to the research.
However, all the participants still had another type of antibody that neutralizes the coronavirus’s spike protein, though its levels decreased, too.
Still, antibodies are not the only way the human body can fight off a virus. It also uses T cells to kill the virus and B cells to rapidly produce new antibodies. Neither of those were measured in the new study.
Vaccines may not protect everybody equally
Ted S. Warren/Associated Press
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said in a livestreamed conversation earlier this month that immune responses to the coronavirus are inconsistent between different patients.
“I have examples of people who were clearly infected, who are antibody-negative,” Fauci said, adding that those people likely have antibodies — just not enough for the test to detect. Other recovered patients, meanwhile, show high antibody counts.
“It isn’t a uniformly robust antibody response,” Fauci added.
Other coronaviruses — the kind that cause common cold — produce immunity that lasts less than a year, and in some cases just a few months.
“It may be completely different with this coronavirus,” Fauci said. “We don’t know.”
Learning more about humans’ natural immune responses to the new coronavirus is crucial, since it informs how a vaccine might work.
“If the body is capable of making an immune response to clear the virus in natural infection, that’s a pretty good proof of concept to say that you’re going to make an immune response in response to a vaccine,” Fauci said.
But he added: “There’s never a guarantee, ever, that you’re going to get an effective vaccine.”
If people who get infected and recover on their own don’t develop a strong immune reponse, that may not bode well for vaccine development. Still, the Wanzhou study is small, so further research could give scientists a better picture of how immune systems respond to COVID-19.
Read the original article on Business Insider